Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura

• DOI: 10.1016/j.transci.2018.02.003
• Publication Date: 2018-02-09T13:11:32Z
• Authors: Esra Terzi Demirsoy; Ozgur Mehtap; Elif Birtas Atesoglu; Pinar Tarkun; Necmi Eren; Ayfer Gedük; Abdullah Hacihane...
• Keywords: Adult; Male; 03 medical and health sciences; 0302 clinical medicine; Purpura, Thrombotic Thrombocytopenic; Dasatinib; Humans; Antineoplastic Agents; 3. Good health

Most commonly seen side effects with Tyrosine kinase inhibitors (TKI's) are hematologic toxicities. Besides, with dasatinib autoimmune side effects can be seen. Thrombotic thrombocytopenic purpura (TTP) is a life- threatening disease that can be related to various causes mainly autoimmune disorders or antineoplastic drugs. Few cases of TKI associated secondary thrombotic microangiopathies (TMA) have been reported in literature. Most of cases were diagnosed as hemolytic uremic syndrome (HUS) rather than TTP. Herein, we describe a 37-year-old CML patient who was diagnosed as immune-mediated TTP related to dasatinib.